
    
      An Open-Label, Randomized, Multi-Site Study to Assess the Pharmacokinetics of Single
      Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered at Three Different
      Injection Sites in Adult Male and Female Subjects with Type 2 Diabetes and of Single
      Subcutaneous Injections of 16mg and 64mg of GSK716155 Administered in the Abdomen of Healthy,
      Normal Volunteers
    
  